The hallmark of Bioventix's corporate strategy is its capital-light, royalty-intensive financial model. Unlike traditional biopharmaceutical enterprises burdened by large clinical trial costs, Bioventix licenses antibodies to diagnostic partners in exchange for ongoingRoyaltystreams based on end-user test kit sales. Bioventix maintains an notable dividend track …
The recommendation is supported by a phase IIIb trial involving 312 participants, which met its primary endpoint and showed that immune memory from vaccination in infancy can be boosted up to 19 years later. GSK says a booster could help maintain protection into adolescence, …
This week, the shares remained under pressure. On 9 November, Haleon was the biggest faller in the FTSE 100, down 2.39% to 330.8p, as investors sold defensive names to chase cyclical stocks during a risk-on rally. By Friday, 13 November, the rotation back into …
Eco Animal Health's financial half-year ends in September, and its interim results are typically published towards the end of the calendar year, so the company is moving into a period of heightened attention. As a small-cap value stock with established products and a cash-backed …
That firmer tone at the top of the sector tends to spill over into smaller biotech companies, where investors look for early-stageAssetswith the potential to address significant unmet medical needs. For HemoGenyx, a small-cap growth stock, attention centres on its lead cell therapy for …
Autoimmune disease remains one of the largest areas of unmet medical need, and new mechanisms that could modulate the immune system without broad suppression are of particular interest. For a small-cap growth stock such as ImmuPharma, attention tends to centre on the next steps …
The broader market showed a firm tone at the top end, with the FTSE 100 at a three-month high, while AIM was broadly flat. Digital health, particularly services linked to weight management medications, remains one of the fastest-growing segments of consumer healthcare, and MedPal …
The microbiome, the community of bacteria living in and on the human body, has become one of the most discussed areas in consumer health and life sciences. For a small-cap growth stock such as SkinBioTherapeutics, attention tends to centre on commercial traction of its …
Why is LSE:CTEC in focus today? The first reason is the interaction between recent trading momentum and expectations for the next corporate milestone. Investors tend to react most strongly when a company is approaching results, a trading update, a regulatory decision, a financing event, …
• The stock is classified as a small-cap growth stock; this is a descriptive market classification, not anInvestmentrating.